fda warning compounding semaglutide october 2025 Warns on Certain Forms of Compounded 📢 FDA has determined the

Before determining that a shortage is resolved, FDA considers a variety of factors, including the company's ability to meet current and historical demand, the amount in a manufacturers stock, affected market share, ability of alternate manufacturers to cover the demand, and confirmed market stabilization

Given the similarities between the brain's and retina's vascular systems, these findings suggest that GLP-1R agonism could also protect the brain's microvasculature, preserving the integrity of the blood-brain barrier and improving cerebral blood flow

Dip in when you want tips or motivation or just use the tools that work for you

The fatigue has a physical quality to it, not just mental fog but actual limb heaviness

What about regulatory scrutiny

95% CI, 0.14 to 1.91